Neurotransmitter Uptake Inhibitors
"Neurotransmitter Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that inhibit the transport of neurotransmitters into axon terminals or into storage vesicles within terminals. For many transmitters, uptake determines the time course of transmitter action so inhibiting uptake prolongs the activity of the transmitter. Blocking uptake may also deplete available transmitter stores. Many clinically important drugs are uptake inhibitors although the indirect reactions of the brain rather than the acute block of uptake itself is often responsible for the therapeutic effects.
| Descriptor ID |
D014179
|
| MeSH Number(s) |
D27.505.519.562.437 D27.505.519.625.600 D27.505.696.577.600
|
| Concept/Terms |
Neurotransmitter Uptake Inhibitors- Neurotransmitter Uptake Inhibitors
- Uptake Inhibitors, Neurotransmitter
- Reuptake Inhibitors, Neurotransmitter
- Inhibitors, Neurotransmitter Reuptake
- Neurotransmitter Reuptake Inhibitors
- Transmitter Uptake Inhibitors, Neuronal
- Inhibitors, Neurotransmitter Uptake
|
Below are MeSH descriptors whose meaning is more general than "Neurotransmitter Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Neurotransmitter Uptake Inhibitors".
This graph shows the total number of publications written about "Neurotransmitter Uptake Inhibitors" by people in this website by year, and whether "Neurotransmitter Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 0 | 1 |
| 2008 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Neurotransmitter Uptake Inhibitors" by people in Profiles.
-
A PET study of tiagabine treatment implicates ventral medial prefrontal cortex in generalized social anxiety disorder. Neuropsychopharmacology. 2009 Jan; 34(2):390-8.
-
Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment. J Psychiatr Res. 2008 Oct; 42(12):1042-9.
-
The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry. 2005 Nov; 66(11):1401-8.